National Cancer Institute (nci)

This study tests a vaccine called SurVaxM in 80 current or former smokers at high risk for lung cancer. The vaccine trains the immune system to attack cells that make a protein called survivin, which is common in cancer cells. The goal is to see if the vaccine can trigger a stron…

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…

This study looks at two groups of people whose Hodgkin lymphoma has returned or not responded to first treatment. For standard-risk patients, it compares a new drug combo (brentuximab vedotin and nivolumab) after radiation to the usual high-dose chemo plus stem cell transplant. F…

This early-stage trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has come back or not improved after prior therapy. The drug works by attaching to both cancer cells and immune cells, helping the immune system attack the lymphoma. The study aims…

This study tests whether adding the drug venetoclax to standard chemotherapy before and after a stem cell transplant can help prevent acute myeloid leukemia (AML) from coming back. About 244 adults with AML in first remission will receive either venetoclax or a placebo alongside …

This early-phase trial tests a new form of tin-based radiation drug (Sn-117m-DTPA) designed to target cancer that has spread to the bones from prostate, breast, or lung cancer. The drug delivers low-level radiation directly to bone tumors while being gentler on the bone marrow. T…

This study tests whether a new combination of two drugs (sacituzumab govitecan and bevacizumab) works better than the standard treatment for a specific type of ovarian cancer. The cancer must have come back after initial platinum therapy and stopped responding to a PARP inhibitor…

This early-stage trial tests a new two-drug combination for people whose glioblastoma (a severe brain cancer) has returned. One drug, Actimab-A, uses a radioactive particle attached to an antibody to seek out and destroy cancer cells. The other, cemiplimab, helps the immune syste…

This study tests adding a new drug, iberdomide, to standard chemoimmunotherapy for children and young adults (ages 1-30) whose neuroblastoma has returned, not responded, or worsened after prior treatment. The goal is to see if the combination is safe and works better at controlli…

This study tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can clear tiny traces of colorectal cancer detected in the blood after standard treatment. About 20 adults with stage II or III colorectal cancer who have cancer DNA in their bloodstr…

This early-phase study tests a personalized cell therapy for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that came back after standard treatment. Researchers take a patient's own immune cells, modify them to recognize a protein called B7-H…

This study compares a new two-drug combination (daratumumab and teclistamab) to standard three-drug treatments for people with high-risk multiple myeloma that has returned or not responded to initial therapy. About 80 adults who have had only one prior treatment line will be rand…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This early-phase trial tests the safety and best dose of glofitamab when given with standard chemotherapy (R-CHOP/R-DHAP) for people with untreated mantle cell lymphoma. About 16 adults aged 18 to 75 with stage II bulky, III, or IV disease will take part. The goal is to see if ad…

This study tests whether giving the immunotherapy drug atezolizumab after surgery can prevent stage I lung cancer from returning. About 336 people who have had their lung cancer completely removed will either receive the drug or be watched closely. The goal is to see if the drug …

This study tests whether adding the drug olutasidenib to standard treatments helps people with certain types of blood cancer (MDS or AML) that have an IDH1 gene mutation. About 132 adults will take part. The goal is to see if the new combination leads to higher remission rates an…

This study tests whether adding newer drugs to standard chemotherapy can better eliminate leftover leukemia cells in adults (ages 18-59) before a stem cell transplant. About 184 participants will receive one of four treatment combinations. The goal is to achieve a deeper remissio…

This study tests whether adding another drug to luspatercept helps treat low-risk myelodysplastic syndrome (MDS) with anemia. About 270 adults will receive luspatercept alone or with epoetin alfa or emavusertib. The goal is to see if these combinations improve red blood cell coun…

This study tests a new vaccine (TriAdeno) plus an immune-boosting drug (N-803) in men with early-stage prostate cancer who are currently just monitoring their cancer. The goal is to see if this combination can stop tumors from growing and reduce the need for more aggressive treat…

This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer ce…

This phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…

This study tests a stem cell transplant approach for people aged 4 to 70 whose blood cancer is caused by an inherited RUNX1 gene mutation. The key idea is to tailor chemotherapy and supportive care doses to each patient, aiming for better disease-free survival than standard metho…

This early-phase trial is testing whether giving two immunotherapy drugs (botensilimab and balstilimab) before surgery can help treat high-risk clear cell kidney cancer that hasn't spread. About 16 adults will receive the drugs before having their kidney tumor removed. The main g…

This study tests a new combination of teclistamab and pomalidomide against the usual treatment (carfilzomib, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned after initial treatment. The goal is to see if the new combo is safe and better at reducing…

This study tests whether adding the antifungal drug itraconazole to standard ablation therapy can prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 participants will receive either itraconazole or a placebo alongside their usual endoscopic ablation.…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other parts of the body but not yet to the brain. Researchers will analyze these samples for tumor DNA that might help predict…

This study screens up to 1,000 people with personal or family histories of certain cancers or genetic syndromes to see if they qualify for one of several ongoing genetics research studies. Participants fill out a 15-20 minute online survey about their health and family history. N…